Eli Lilly and Company announced this week that it will offer an authorized generic version of the insulin Humalog (insulin lispro injection 100 units/mL) to U.S. pharmacies 50 percent lower than current list price – a move the company said in a press release that is intended to help patients better afford the out-of-pocket expense of obtaining the diabetes medication. "We've engaged in discussions about the price of insulin with many different stakeholders in America's healthcare system: people living with diabetes, caregivers, advocacy groups, health care professionals, payers, wholesalers, lawmakers, and leading health care scholars," said David A. Ricks, Lilly's chairman and chief executive officer in a prepared statement. "Solutions that lower the cost of insulin at the pharmacy have been introduced in recent months, but more people need help. The significant rebates we pay on insulins do not directly benefit all patients. This needs to change."